Lomefloxacin is an effective treatment of experimental bacterial keratitis

Abstract

Purpose: Lomefloxacin was evaluated as a potential topical therapy for bacterial keratitis.

Methods: Lomefloxacin was compared with ciprofloxacin in different rabbit keratitis models. A total of 216 corneas were infected with Staphylococcus aureus (ciprofloxacin-susceptible and -resistant), Streptococcus viridans, Streptococcus pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens and were treated with lomefloxacin (0.3%), ciprofloxacin (0.3% Ciloxan), and the control phosphate-buffered saline (PBS), respectively. The data were analyzed statistically comparing the decrease in the number of recovered viable bacteria.

Results: Compared with PBS-treated control corneas, the colony counts for all bacterial isolates were significantly reduced (p < 0.05) after topical treatment with either lomefloxacin or ciprofloxacin. For gram-positive bacteria, lomefloxacin and ciprofloxacin were equally effective. For gram-negative bacteria, lomefloxacin, while effective, was less so than ciprofloxacin under experimental conditions (p < 0.05).

Conclusion: Our data, using multiple bacterial keratitis models, suggest that lomefloxacin is promising for therapy of bacterial keratitis. Further clinical studies are needed to expand its use for keratitis therapy.